Department of Functional Neurosurgery, CHU Timone, APHM, Marseille, France.
J Neurosurg. 2012 Nov;117(5):877-85. doi: 10.3171/2012.7.JNS10672. Epub 2012 Aug 31.
The aim of this study was to perform an accurate analysis of changes in hearing in patients with vestibular schwannoma (VS) who have undergone Gamma Knife surgery (GKS) and distinguish the impact of radiosurgery from the natural course of hearing deterioration due to the tumor itself.
This study was a retrospective review of prospectively collected patient data. A group of 154 patients with unilateral nonsurgically treated VS was conservatively monitored for more than 6 months and then treated with GKS between July 1997 and September 2005. They were followed up with serial clinical examination, MRI, and audiometry. The annual hearing decrease rate (AHDR) was measured before and after radiosurgery, and the possible prognostic factors for hearing preservation were investigated.
The mean dose prescribed to the tumor margins was 12.1 Gy. The mean radiological follow-up period after GKS was 60 months (range 7-123 months). The tumor control rate was 94.8%, and 8 patients underwent subsequent intervention due to tumor progression. The mean audiological follow-up times before and after GKS were 22 and 52 months, respectively. The mean AHDRs before and after GKS were 5.39 dB/year (95% CI 3.31-7.47 dB/year) and 3.77 dB/year (95% CI 3.13-4.40 dB/year), respectively (p > 0.05). The mean pre- and post-GKS AHDRs in patients who initially had Gardner-Robertson (GR) Class I hearing were -0.57 dB/year (95% CI -2.95 to 1.81 dB/year) and 3.59 dB/year (95% CI 2.52-4.65 dB/year), respectively (p = 0.007). The mean pre- and post-GKS AHDRs in patients who initially had GR Class II hearing were 5.09 dB/year (95% CI 1.36-8.82 dB/year) and 4.98 dB/year (95% CI 3.86-6.10 dB/year), respectively (p > 0.05). A subgroup of 80 patients had both early and late post-intervention AHDR assessment (with early referring to the period from GKS to the assessment closest to the 2-year follow-up point and late referring to the period from that assessment to the most recent one); in these patients, the mean early post-GKS AHDR was 5.86 dB/year (95% CI 4.25-7.50 dB/year) and the mean late post-GKS AHDR was 1.86 dB/year (95% CI 0.77-2.96 dB/year) (p < 0.001). A maximum cochlear dose of less than 4 Gy was found to be the sole prognostic factor for hearing preservation.
The present study demonstrated the absence of an increase in AHDR after radiosurgery as compared with the preoperative AHDR. There was even a trend indicating a reduction in the annual hearing loss after radiosurgery over the long term. To fully elucidate a possible protective effect of radiosurgery, longer-term follow-up with a larger group of patients will be required.
本研究旨在对接受伽玛刀手术(GKS)治疗的前庭神经鞘瘤(VS)患者的听力变化进行准确分析,并区分放射外科治疗与肿瘤本身导致的听力恶化的自然病程的影响。
这是一项前瞻性收集患者数据的回顾性研究。一组 154 例未经手术治疗的单侧 VS 患者接受了超过 6 个月的保守监测,然后于 1997 年 7 月至 2005 年 9 月接受 GKS 治疗。他们接受了连续的临床检查、MRI 和听力测试。在放射外科治疗前后测量每年听力下降率(AHDR),并研究了听力保护的可能预后因素。
肿瘤边缘处方剂量的平均值为 12.1 Gy。GKS 后平均放射学随访时间为 60 个月(范围 7-123 个月)。肿瘤控制率为 94.8%,8 例因肿瘤进展而接受后续干预。放射外科治疗前后平均听力随访时间分别为 22 个月和 52 个月。放射外科治疗前后平均 AHDR 分别为 5.39 dB/年(95% CI 3.31-7.47 dB/年)和 3.77 dB/年(95% CI 3.13-4.40 dB/年)(p > 0.05)。最初听力为 Gardner-Robertson(GR)分级 I 的患者放射外科治疗前后的平均 AHDR 分别为-0.57 dB/年(95% CI -2.95 至 1.81 dB/年)和 3.59 dB/年(95% CI 2.52-4.65 dB/年)(p = 0.007)。最初听力为 GR 分级 II 的患者放射外科治疗前后的平均 AHDR 分别为 5.09 dB/年(95% CI 1.36-8.82 dB/年)和 4.98 dB/年(95% CI 3.86-6.10 dB/年)(p > 0.05)。80 例患者中有一组进行了早期和晚期介入后 AHDR 评估(早期指从 GKS 到最接近 2 年随访点的评估期间,晚期指从该评估到最近一次评估期间);这些患者中,放射外科治疗后早期平均 AHDR 为 5.86 dB/年(95% CI 4.25-7.50 dB/年),放射外科治疗后晚期平均 AHDR 为 1.86 dB/年(95% CI 0.77-2.96 dB/年)(p < 0.001)。发现耳蜗最大剂量小于 4 Gy 是听力保护的唯一预后因素。
本研究表明,与术前 AHDR 相比,放射外科治疗后 AHDR 无增加。甚至有长期趋势表明放射外科治疗后每年听力损失减少。为了充分阐明放射外科治疗的可能保护作用,需要对更大的患者群体进行更长期的随访。